機構拋售!華海藥業(600521.SH)連續第二日跌停,股價創逾1年新低
格隆匯4月8日丨繼昨日跌停後,華海藥業(600521.SH)今日再度跌停,報20.21元,股價創2020年3月以來新低,最新市值294億元,兩日市值蒸發近69億元。昨日盤後龍虎榜數據顯示,華海藥業買入前五席位資金淨流入7631.44萬元,但5家機構席位合計淨賣出高達2.67億。華海藥業主營業務為原料藥及醫藥中間體的製造和銷售。值得注意的是,公司到目前為止還未公佈年度業績,有投資者懷疑華海醫藥目前的大跌與業績有關。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.